1. The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients.
- Author
-
Hu, Shunfeng, Chen, Na, Lu, Kang, Zhen, Changqing, Sui, Xiaohui, Fang, Xiaosheng, Li, Ying, Luo, Yingshu, Zhou, Xiangxiang, and Wang, Xin
- Subjects
- *
DIFFUSE large B-cell lymphomas , *VIRAL antibodies , *HEPATITIS B virus , *OVERALL survival , *DISEASE risk factors , *VIRUS diseases - Abstract
Diffuse large B-cell lymphoma (DLBCL) has been correlated with virus infection and immunity status. We retrospectively analyzed the association between HBV antibody and DLBCL development in HBsAg- patients. Compared with HBeAb- patients, HBeAb+ patients displayed unique clinical features. HBV antibody-negative patients had better therapeutic efficiency (p <.05). The media progression-free survival (PFS) and overall survival (OS) of HBV antibody-positive group were shorter than the negative group (p <.05). Furthermore, we found positive association between CD21 and HBsAb and their synergistic effect for prognostic predication. Interestingly, the effect of Rituximab in prognostic improvement was more significant in HBV antibody-positive group than negative group. Univariate analysis showed that HBV antibody was independent risk factor for disease prognosis. Altogether, our investigations identified for the first time the close association between HBV antibody and clinical prognosis in DLBCL patients. These findings provide potential biomarker to predict the effect of Rituximab and prognosis in DLBCL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF